Back to Agenda
[V2-S1] The Methodology of Health Technology Assessment (HTA) in Japanese
Session Chair(s)
Kuniko Shoji
Vice-Dean, School of Health Innovation
Kanagawa University of Human Services, Japan
As innovative and expensive pharmaceuticals and medical devices are increasingly used in clinical practice, Health Technology Assessment (HTA) is attracting serious attention as a policy making tool to enable sustainability of universal access. The HTA, which has been implemented on a trial basis since 2016, is actively discussing how the system should be designed in readiness for a full-scale implementation. At the Japan Annual Meeting in 2017, we will give an overview of insurance reimbursement, drug pricing system, etc. of both foreign countries and Japan, and will conduct a free and open panel discussion from various viewpoints concerning cost-effectiveness assessment in Japan. In this way, we plan to discuss the methodology of a comprehensive evaluation of HTA in Japanese and the value of life for Japanese people (ICER threshold).
Speaker(s)
Introduction of Insurance Reimbursement, Drug Pricing System of Both Foreign Countries and Japan
Ataru Igarashi, PhD
Yokohama City University , Japan
Current Status of Cost-Effectiveness Assessment in Japan
Makoto Kobayashi, PhD
CRECON Medical Assessment Inc., Japan
Director and Chief Operating Officer
Takeo Nakayama, MD, PhD
Takeo Nakayama, MD, PhD
Kyoto University, Graduate School of Medicine and Faculty of Medicine, Japan
Professor, Department of Health Informatics, School of Public Health
Rei Goto, MD, PhD
Rei Goto, MD, PhD
Keio University, Japan
Associate Professor, Graduate School of Business Administration
Harumichi Okamura
Harumichi Okamura
Novartis Pharma K.K., Japan
Corporate Officer, Head of Market Access & Public Affairs
Have an account?